Privi Speciality Chemicals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/josijssr20ucw6nolnsj58i7.pdf

Key Takeaways


Quarterly Performance & Margin Drivers

Babani: "We are confident of maintaining 20% or beating 20%, be honest. We are confident that we'll be able to be close to INR4,000 crores, maybe INR3,750 or some number, but we are close to guidance what we have given. 20% will be surely maintained."

Balance Sheet & Working Capital

Iyer: "Privi stands for quality on delivery time, and expectations of the customers have been so good with us that they have been helping us in ensuring that the money is paid to us on time and in some cases, maybe a few days before time also."

Capacity Expansion & Capex Roadmap

Patil: "You will see part of it coming through in quarter 3, but a significant part would come in quarter 4 because that's when the new contracts really start, which are annual contracts. So we are very positive about those contracts. And you will see significant impact of that capacity utilization of almost 85% to 90% during that quarter for the expanded capacity also."

Subsidiaries & JVs


Market Environment & Competitive Position

Babani: "See, our market's usage of aroma chemicals is increasing significantly. Lots of new things are coming, new people are using more and more pinene. Africa market is growing. So for us, we supply to markets -- customers who supply to Africa. So the markets are really growing well, and we hope to maintain the 20% target as committed."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growthMaintain or beat 20% growth; revenue close to ₹3,750–4,000 croresFY27 full year
FY27 EBITDA marginMaintain at current levelsFY27 full year
Phase 1 capacity utilizationRamp to 85–90% for expanded capacityQ4 FY27
Phase 2 capex completionMaltol, ethyl maltol, furfural derivatives plant complete; ~₹1,000 crores revenue at full capacityCompletion Jun–Sep 2027; revenue from Oct 2027
Phase 3 capex₹400–425 crores capex for ₹450–500 crores additional revenueIn sync by 2030
5K:1K plus visionReach ₹5,000 crores revenueBy 2030
Privi Fine Sciences mergerMerger process completedBefore end of FY27
Privi Fine Sciences revenue scale-upRevenue from ~₹100 crores to ₹250–300 croresNext financial year (FY28)
PRIGIV JV revenue~₹225 crores, with potential upside from a third phase under studyFY27–28
Working capital cycle105–110 daysLong-term annual expectation
State incentivesTotal FY27 higher than previous yearNext 6 months

Key Metrics

MetricQ2 FY27
Total revenue₹773.16 cr, up 13.9% YoY, highest ever quarterly
EBITDA₹212.49 cr, up 16.66% YoY, highest ever quarterly
Profit after tax₹117.03 cr, up 24.61% YoY
EBITDA margin27.48%, vs 26.12% in FY26
H1 FY27 PAT₹201 cr, up ~29% YoY
RMC as % of sales~52%, vs 54% in Q1 FY27 and 51% in Q2 FY26
Other expenses as % of sales9.72%
State incentives received₹1.62 cr in H1 FY27, vs ₹9 cr in H1 FY26; ₹12–15 cr expected in H2
ROCE24.30%, improvement of 216 bps YoY
ROE26.34%, increase of 134 bps YoY
Net debt₹814.51 cr; net debt-to-EBITDA 1.07x, net debt-to-equity 0.51x
Working capital cycleLess than 100 days, vs 124 days in Q2 FY26; long-term expectation 105–110 days
Cash generated from operations (H1 FY27)₹445 cr
Asset turnover1.7x on fixed asset base
Volume growth4% YoY in Q2; ~7–7.5% YoY in H1
Phase 1 capacity expansionCompleted as of 30 Sep 2026; installed capacity increased from 48,000 MTPA to 54,000 MTPA
PRIGIV JV revenue~₹28 cr in Q2, with positive PBT of ~₹2 cr; H1 revenue ~₹47 cr
FY27 revenue guidance20% growth or better; confident of being close to ₹4,000 cr, maybe ₹3,750 cr
Interim dividend₹5 per share, first ever interim dividend